Ponesimod

Ponesimod
Clinical data
Trade namesPonvory
Other namesACT-128800
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Metabolism2 main metabolites
Elimination half-life31–34 hrs[7]
ExcretionFeces (57–80%, 26% unchanged), urine (10–18%)[8]
Identifiers
  • (2Z,5Z)-5-{3-Chloro-4-[(2R)-2,3-dihydroxypropoxy]benzylidene}-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-4-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H25ClN2O4S
Molar mass460.97 g·mol−1
3D model (JSmol)
  • CCC/N=C\1/N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C
  • InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23-/t17-/m1/s1
  • Key:LPAUOXUZGSBGDU-STDDISTJSA-N

Ponesimod, sold under the brand name Ponvory, is a medication for the treatment of multiple sclerosis.[4][9] It is a sphingosine-1-phosphate receptor modulator.[4]

The most common side effects include upper respiratory tract infection, hepatic transaminase elevation, and hypertension.[4][5][9]

Ponesimod was approved for medical use in the United States in March 2021,[4][9] and in the European Union in June 2021.[10]

  1. ^ a b "Ponvory APMDS". Therapeutic Goods Administration (TGA). 24 March 2022. Retrieved 4 April 2022.
  2. ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Retrieved 2 January 2023.
  3. ^ "Summary Basis of Decision (SBD) for Ponvory". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  4. ^ a b c d e "Ponvory- ponesimod tablet, film coated Ponvory- ponesimod kit". DailyMed. Archived from the original on 21 January 2022. Retrieved 31 March 2021.
  5. ^ a b Cite error: The named reference Ponvory EPAR was invoked but never defined (see the help page).
  6. ^ "Ponvory Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  7. ^ Cite error: The named reference Brossard was invoked but never defined (see the help page).
  8. ^ Cite error: The named reference Reyes was invoked but never defined (see the help page).
  9. ^ a b c "Janssen Announces U.S. FDA Approval of Ponvory (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio (teriflunomide) in Reducing Annual Relapses and Brain Lesions" (Press release). Janssen. 19 March 2021. Archived from the original on 19 March 2021. Retrieved 19 March 2021 – via PR Newswire.
  10. ^ "European Medicines Agency Approval of Ponesimod". 24 March 2021. Archived from the original on 4 August 2021. Retrieved 4 August 2021.